AZD8233

DRUG4 trials

Sponsors

AstraZeneca

Conditions

DyslipidaemiaEnd Stage Renal DiseaseHypercholesterolemiaHyperlipidaemia

Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

CompletedNCT03593785

AstraZenecaHypercholesterolemia

Start: 2018-08-03End: 2020-12-19Updated: 2021-01-25

To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

TerminatedNCT05065463

AstraZenecaEnd Stage Renal Disease

Start: 2022-08-10End: 2022-11-23Updated: 2022-12-22

Phase 2

A Study of AZD8233 in Participants With Dyslipidemia

CompletedNCT04641299

AstraZenecaDyslipidaemia

Start: 2020-10-28End: 2021-07-20Updated: 2022-11-18

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia

CompletedNCT04964557

AstraZenecaHyperlipidaemia

Start: 2021-07-07End: 2022-07-15Updated: 2023-12-15

Related Papers

Population pharmacokinetics of a novel <i>PCSK9</i> antisense oligonucleotide

British Journal of Clinical Pharmacology2024-03-194 citations

Abstract 11482: The PCSK9-Targeted Antisense Oligonucleotide AZD8233 Reduces LDL-C, ApoB, and Lp(a) in Patients With Dyslipidemia on Statin Treatment - Data From the Phase 2b ETESIAN Study

Circulation2022-11-084 citations

Abstract 9747: Safety, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD8233, Targeting PCSK9, in Patients with Dyslipidemia

Circulation2021-11-163 citations

Abstract 13913: Single Dose Safety, Pharmacokinetics, and Pharmacodynamics of a Potent PCSK9 Synthesis Inhibitor, AZD8233, in Subjects With Elevated Ldl Cholesterol

Circulation2020-11-171 citations